STOCK TITAN

Bio-Techne Corp Stock Price, News & Analysis

TECH Nasdaq

Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.

Bio-Techne Corporation (NASDAQ: TECH) provides this centralized hub for investors and industry professionals tracking developments in life sciences innovation. Access official press releases, financial disclosures, and strategic updates from the global leader in bioactive reagents and diagnostic solutions.

This resource delivers timely updates on earnings results, product launches, and strategic collaborations critical to understanding the company's position in biotechnology markets. Users will find announcements related to protein analysis advancements, spatial biology innovations, and global distribution partnerships.

All content is sourced directly from Bio-Techne's corporate communications, ensuring accuracy for those monitoring investment opportunities or industry trends. Bookmark this page for efficient access to material developments affecting TECH's market performance and scientific impact.

Rhea-AI Summary

Bio-Techne (NASDAQ: TECH) has announced the European launch of the CE-IVD marked RNAscope ISH Probe High Risk HPV. This tool is designed for the accurate detection of HPV mRNA in patients with oropharyngeal squamous cell carcinoma (OPSCC). Compared to traditional methods like immunohistochemistry (IHC) for p16 protein, which can misdiagnose by 5-20%, the RNAscope ISH offers superior accuracy for identifying high-risk HPV types. This advancement allows clinicians to improve patient management and diagnosis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.13%
Tags
none
-
Rhea-AI Summary

Bio-Techne Corporation (NASDAQ:TECH) has completed its acquisition of Namocell, Inc. This acquisition enhances Bio-Techne's capabilities by integrating Namocell's single cell sorting and dispensing technologies, which are vital for biotherapeutics and diagnostics workflows. Key applications include cell and gene therapy development, single cell genomics, and antibody discovery. The deal positions Bio-Techne to leverage these innovative technologies for growth in the biotechnology sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.58%
Tags
-
News
Rhea-AI Summary

Bio-Techne Corporation (NASDAQ:TECH) has announced its intention to acquire Namocell, Inc., a leader in single cell sorting technology, expected to close in Q1 of fiscal 2023. The acquisition aims to enhance Bio-Techne's Cell and Gene Therapy franchise, with Namocell's innovative technology offering significant advantages over traditional methods like flow cytometry. Namocell's products facilitate quick and gentle sorting of single cells, critical for various applications in biotherapeutics and diagnostics. This strategic move is anticipated to generate commercial synergies for Bio-Techne.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.55%
Tags
none
-
Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) announced the publication of a global study in the Journal of Electrophoresis, assessing the comparability of its iCE3 and Maurice analytical platforms for charge heterogeneity analysis of therapeutic proteins. The study involved 19 sites across the US, Europe, and China, demonstrating excellent comparability with less than 1.02% standard deviation for charge variants and high precision for isoelectric point values. This advancement supports biopharmaceutical companies in transitioning to the Maurice system, enhancing its market presence and credibility in GMP quality control.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
none
-
Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) announced that CEO Chuck Kummeth will present at the Jefferies 2022 Healthcare Conference on June 8, 2022, at 9:30 a.m. EDT. Investors can access the live webcast through Bio-Techne's Investor Relations website. The company is a leader in developing high-quality purified proteins, reagents, and diagnostic products, generating approximately $931 million in net sales in fiscal 2021. With a workforce of around 2,700, Bio-Techne plays a vital role in scientific research and clinical diagnostics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.05%
Tags
conferences
Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) has entered a partnership with Nonagen Bioscience to exclusively manufacture the Oncuria bladder cancer diagnostic panel. Oncuria utilizes xMAP Luminex technology to provide early detection, therapy selection, and monitoring of bladder cancer. The test received FDA Breakthrough Device Designation in September 2021, which facilitates expedited review and collaboration with the FDA. The Oncuria test is expected to be available by Q4 2022, promising improved patient outcomes through enhanced cancer detection capabilities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.01%
Tags
none
-
Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) announced a significant scientific presence at the American Urological Association Conference from May 13-16, 2022, in New Orleans, LA. Exosome Diagnostics will present two posters and conduct six in-booth scientific presentations, including a live symposium with Cal Ripken, Jr. and Dr. Ronald Tutrone. Key presentations include biomarker studies on prostate cancer and kidney transplant rejection. The ExoDx Prostate test plays a crucial role in early detection, supported by Medicare. One in nine American men will face prostate cancer in their lifetime, highlighting the need for awareness.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
conferences
-
News
Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) announced a quarterly dividend of $0.32 per share for the quarter ending March 31, 2022. This dividend will be payable on May 27, 2022 to shareholders of record as of May 16, 2022. The company reported approximately $931 million in net sales for fiscal 2021 and continues to provide innovative tools for the life sciences industry. Future dividends will be evaluated quarterly by the Board of Directors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.24%
Tags
dividends
Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) reported strong financial results for Q3 FY2022, with organic revenue growth of 17% to $290.4 million. GAAP EPS was $1.48, up from $1.12 last year, while adjusted EPS rose to $2.14 from $1.80. Key highlights include 16% organic growth in Protein Sciences and 19% in Diagnostics and Genomics. The company also announced a partnership with Thermo Fisher Scientific for the ExoTRU kidney transplant rejection test. Adjusted operating income increased 17% to $114.6 million, maintaining a robust adjusted operating margin of 39.6%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.24%
Tags

FAQ

What is the current stock price of Bio-Techne (TECH)?

The current stock price of Bio-Techne (TECH) is $54.2 as of September 9, 2025.

What is the market cap of Bio-Techne (TECH)?

The market cap of Bio-Techne (TECH) is approximately 8.4B.
Bio-Techne Corp

Nasdaq:TECH

TECH Rankings

TECH Stock Data

8.42B
153.84M
1.09%
102.49%
4.04%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
MINNEAPOLIS